The UK and US have announced a significant bilateral deal that will keep zero levies on British medicine exports entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has committed to raise expenditure on drugs through the NHS. This pledge guarantees that tariffs on these key exports will stay at zero for a period of the next three years.
This agreement is in response to recent warnings to hike tariffs on patented pharmaceutical imports, with potential rates floated as high as double the cost.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue equity to U.S.–U.K. drug exports," a statement declared.
Economic Impact
Pharmaceuticals represent one of the Britain's most significant goods shipped to the US, which is by far the largest market for large British pharmaceutical firms.
Statistics show that in the one-year period leading up to September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that period.
"This agreement secures employment, boosts capital expenditure and paves the way for the UK to become a worldwide center for biotech and pharma," a government official commented.
Specific British Pledges
The agreement involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double overall NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds exceeded twenty percent.
Industry Background
The deal comes amid a protracted row between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were heightened by arguments that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
One official acknowledged that the NHS must spend more on medicines, noting that its spending on drugs had decreased as a proportion of its total funding over the last ten years.
